---
schema_version: "secwatch.filing_event.v1"
accession: "0001082554-25-000036"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:34:25.028992+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics reports record Q3 revenue $799.5M (+7% YoY); EPS $7.16 diluted, TETON-2 breakthrough

## Summary
- Revenue $799.5M (+7% YoY); net income $338.7M (+10%); diluted EPS $7.16 vs $6.39.
- Tyvaso DPI sales $336.2M (+22% YoY) driving total Tyvaso growth to $478M (+10%).
- Orenitram $131.1M (+16%); Unituxin $47.9M (-22%) offset by price increases.
- TETON-2 study in IPF shows breakthrough results; could significantly broaden therapeutic reach.
- Entered $1B accelerated share repurchase in Aug 2025; received 2.6M shares in Q3 (combined $2B since Mar 2024).

## SEC filing metadata
- accession: 0001082554-25-000036
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000108255425000036/0001082554-25-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000108255425000036/uthr-20251029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001082554-25-000036
- JSON: https://secwatch.observer/filing/0001082554-25-000036.json
- Plain text: https://secwatch.observer/filing/0001082554-25-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.